FTC Objections To Pharma Mergers Could Go Unchallenged Following Wilson’s Resignation

The commission no longer has a voice opposing aggressive antitrust enforcement actions and President Biden's replacement may be more receptive to the stance of the three current Democratic commissioners. Amgen’s proposed acquisition of Horizon is facing FTC scrutiny.

FTC building
FTC Commissioner Christine Wilson's resignation will leave the agency with three Democratic commissioners. • Source: Shutterstock

US Federal Trade Commissioner Christine Wilson’s plan to resign, which she announced in a 14 February Wall Street Journal commentary, will leave the agency with three Democratic commissioners and no voice to oppose their enforcement actions. The situation may make the pharmaceutical industry more vulnerable to FTC challenges of proposed mergers, but will likely not change outcomes.

Wilson harshly criticized FTC Chair Lina Khan, saying she was making a “noisy exit” in the face of “continuing lawlessness”...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Compliance

More from Pink Sheet